Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha Lipoic Acid for Cystine Stone Formation
NCT02910531Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystinuria (CSNU) comparing ALA supplement with Placebo (2 arms). Primary endpoint: Cystine Stone Recurrence at 3 years. Started Jun 2017; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
cystinuria (CSNU)
Beyond the preview
Go deeper on NCT02910531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910531.